Role of TPMT and ITPA variants in mercaptopurine disposition.
Tina GerbekMaria Ebbesen SørumJacob NerstingThomas Leth FrandsenMalin Lindqvist AppellKjeld SchmiegelowPublished in: Cancer chemotherapy and pharmacology (2018)
TPMT and ITPA genotypes significantly influence the metabolism of 6MP. DNA-TG may prove to be a more relevant pharmacokinetic parameter for monitoring 6MP treatment intensity than cytosolic metabolites. Prospective trials are needed to evaluate the usefulness of DNA-TGN for individual dose adjustments in childhood ALL maintenance therapy.